Dr. Natasha Leighl and her team at University Health Network published their pilot data on using liquid biopsy testing earlier in a lung cancer patient's journey. Usually, 1) patients with severe enough symptoms of respiratory issues will be imaged. 2) Images and clinical presentation of potential lung cancer will be referred for biopsy. 3) Tissue biopsy will be used to diagnose lung cancer (i.e. pathological diagnosis). 4) Biomarker testing is done on tissue. 5) Patients receive targeted therapy if druggable mutation is found. In Dr. Leighl's study, her team used Follow It through our testing program after step 2. This shortened time from referral to treatment by half (60 days to 30 days).
Congratulations to everyone, especially to the clinical team for continuing to process samples day-in and day-out. This study is an example of ICH having an immediate impact on patients and having long-term effects on cancer care.
Garcia-Pardo M, Czarnecka K, Law JH, Salvarrey A, Fernandes R, Fan J, Corke L, Waddell TK, Yasufuku K, Donahoe LL, Pierre A, Le LW, Ghumman N, Liu G, Shepherd FA, Bradbury P, Sacher A, Stockley T, Pal P, Rogalla P, Tsao MS, Leighl NB.
Melissa K. McConechy, Suzan McNamara, Mathilde Couetoux du Tertre, Karen Gambaro, Maud Marques, Salem Malikic, Ka Mun Nip, Sonal Brahmbhatt, Adrian Kense, Kevin Tam, Rosalia Aguirre Hernandez, Ruth Miller, Madeline Couse, Jas Khattra, David G. Huntsman and Gerald Batist
Roger H.Kim, Anna Lapuk, James Harraway, Eric Lee, Michael Walsh, Eleni Topkas, Victoria Jones, Julie Burn, Tina Baillie, Cathy Lim, Kambin Nejad, Anita Muljono, Eric Gagne, Melissa K. McConechy, Yesser Zein, Fiona Maclean, Anthony J. Gill, Ana Cristina Vargas
Jamieson A, Huvila J, Thompson EF, Leung S, Chiu D, Lum A, McConechy M, Grondin K, Aguirre-Hernandez R, Salvador S, Kean S, Samouelian V, Gougeon F, Azordegan N, Lytwyn A, Parra-Herran C, Offman S, Gotlieb W, Irving J, Kinloch M, Helpman L, Scott SA, Vicus D, Plante M, Huntsman DG, Gilks CB, Talhouk A, McAlpine JN
Teresa H. Praetorius, Vivian Lac, Basile Tessier-Cloutier, Janine Senz, Tayyebeh M. Nazeran, Martin Köbel, Marcel Grube, Bernhard Krämer, Paul J. Yong, Stefan Kommoss, Michael S. Anglesio
Vivian Lac, Tayyebeh M Nazeran, Basile Tessier-Cloutier, Rosalia Aguirre-Hernandez, Arianne Albert, Amy Lum, Jaswinder Khattra, Teresa Praetorius, Madeline Mason, Derek Chiu, Martin Köbel, Paul J Yong, Blake C Gilks, Michael S Anglesio, David G Huntsman
The theme for this year’s World Cancer Day is Close the Care Gap. Health equity is a pillar of our work at Imagia Canexia Health. So today our Chief Medical Officer, Dr. David Huntsman, is opening the conversation to showcase how our community-centered approach to cancer care is improving access to genomic-driven cancer care for all.
The entire month of November is Lung Cancer Awareness Month. ICH is opening up the conversation to showcase how our distributed data-driven approach is improving health equity in lung cancer cures.
